In HER2 positive breast cancer, vaccine reduces recurrence

the ONA take:

According to results presented by The University of Texas MD Anderson Cancer Center at the 2014 American Society of Clinical Oncology's (ASCO) Breast Cancer Symposium in San Francisco, California, GP2, a novel immunotherapy breast cancer vaccine, has demonstrated a reduction in recurrence in patients with breast cancer. Specifically, GP2 reduced recurrence rates by 57% in women with breast cancer.

 

Furthermore, patients with human epidermal growth factor receptor 2 (HER2) +3, the highest overexpression of HER2, experienced no cancer recurrences after receiving the vaccine after trastuzumab therapy.

 

In the randomized, phase 2 study, 89 patients with different levels of HER2 received granulocyte/macrophage colony-stimulating factor (GM-CSF) and the GP2 vaccine, while 91 patients received only GM-CSF. The vaccine administration consisted of six monthly inoculations injected subcutaneously, followed by a booster shot given every 6 months for 2 years. Participants were monitored for approximately 3 years.

 

In the experimental group, 88% of women achieved disease-free survival for the duration of the study compared with 81% of women in the control group, equating to a 37% reduction in recurrence.

In HER2 positive breast cancer, vaccine reduces recurrence
GP2 has demonstrated a reduction in recurrence in patients with breast cancer.

A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings were presented by The University of Texas MD Anderson Cancer Center at the 2014 American Society of Clinical Oncology's Breast Cancer Symposium in San Francisco.

One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression of HER2 (known as HER2 +3) had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody. HER2 is an oncoprotein that promotes tumor growth and is expressed to some extent in 75-80% of breast cancers.

READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs